Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunomedics says lymphoma drug is promising in preclinical studies
Financial Results Total revenue for the first nine months of fiscal 2009 was CAD4.8 million against CAD5.5 million for the first nine months of fiscal 2008. The majority
Financial Results Total revenue for the first nine months of fiscal 2009 was CAD4.8 million against CAD5.5 million for the first nine months of fiscal 2008. The majority
Under the agreement, Janssen may select up to 12 programs from Galapagos’s internally identified rheumatoid arthritis (RA) targets into the alliance. Janssen receives future option rights to exclusively
Out of the 18 patients enrolled, five achieved stable disease lasting greater than three months. Data from the study demonstrates that Panzem NCD (2ME2 or 2-methoxyestradiol), administered as
To date, 60 patients have been enrolled in the Phase I trial with ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase. No dose-limiting toxicity
Ostene is the only available product designed to stop bone bleeding in surgery that does not interfere with bone healing or increase the risk of surgical infections, including
The reduction in Ca125 biomarker provides an early sign that a treatment regimen is effective in combating ovarian cancer. At the reported doses, toxic effects observed were generally
Twice-daily delivery of nebulized formoterol fumarate was well tolerated over a 12-month treatment period in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). Perforomist inhalation solution is the
ARRY-543, a small molecule that is administered orally, was well-tolerated up to 300 mg BID (twice daily). The maximally tolerated dose has not yet been established on the
Results from the ongoing trial suggest the CR011-vcMMAE is well-tolerated at doses up through 1.88 mg/kg with no dose-limiting toxicities noted. Dose- escalation continues with patients currently being
The data shows that significant majority of patients on study have experienced tumor shrinkage with prolonged duration of stable disease, highlight the potential utility of drug and its